Controlling cardiac arrhythmias: To delay conduction or to prolong refractoriness

1 September 1989

journal article
research article
Published by Springer Nature in Cardiovascular Drugs and Therapy

Vol. 3 (5) , 671-674
https://doi.org/10.1007/bf01857618

Abstract

Recent data with encainide and flecainide (CAST study) question the benefit of reducing premature ventricular contractions in survivors of myocardial infarction. Proarrhythmic mechanisms might include excessive slowing of conduction. In patients with supraventricular tachycardias, proarrhythmic effects of Class 1c agents are very uncommon.

This publication has 12 references indexed in Scilit:

Encainide
Cardiovascular Drugs and Therapy, 1989
When is QT prolongation antiarrhythmic and when is it proarrhythmic?
The American Journal of Cardiology, 1989
Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction
The American Journal of Cardiology, 1988
Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS
The American Journal of Cardiology, 1988
Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
Circulation, 1986
The cardiac arrhythmia pilot study
The American Journal of Cardiology, 1986
Control of cardiac arrhythmias by selective lengthening of repolarization: Theoretic considerations and clinical observations
American Heart Journal, 1985
Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification
Cardiovascular Research, 1983
The effect of amiodarone, a new anti‐anginal drug, on cardiac muscle
British Journal of Pharmacology, 1970
A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474
British Journal of Pharmacology, 1970